Article
Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.
Blood advances - 13 Jan 2026
Sudha Parvathi, Pham Phillip, Niu Wen, Liu Enze, Wang Lin, Truong Gillian, Ligocki Cameron, Al-Azzawi Ramzi, Surapenini Malini, Bray Steven M, Vetrini Francesco, Czader Magdalena, Tayeh Marwan K, Lee Kelvin, Abonour Rafat, Suvannasankha Attaya, Walker Brian A
Abstract excerpt
ABSTRACT: Here, we present the case for next-generation sequencing of samples from patients with multiple myeloma (MM), not only identify high-risk markers but also mutations and deletions relating to immunomodulatory drugs (IMiD), and more importantly to guide the sequencing of immunotherapy regimens in response to intrinsic antigen escape as a means of treatment resistance and relapse. This is a single-center...
Read the complete abstract on PubMedTopics
- Humans
- Immunotherapy
- High-Throughput Nucleotide Sequencing
- Biomarkers, Tumor
- Drug Resistance, Neoplasm